Brought to you by 
Alexion, Complement co-develop CP010 for neurodegenerative disorders; Alexion has option to acquire company
Jun 2018
Executive Summary
Alexion Pharmaceuticals Inc. and Complement Pharma are collaborating on the development of Complement's CP010 for neurodegenerative disorders.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com